Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

December 11, 2007 09:00 ET

Stem Cell Therapeutics Corp. Supports the Canadian endMS Research Conference

CALGARY, ALBERTA--(Marketwire - Dec. 11, 2007) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) is pleased to announce that Drs. Trina Johnson, Wee Yong and Samuel Weiss will be presenting preliminary results from a study of the pro-inflammatory effects of prolactin in a mouse model of Multiple Sclerosis (MS) at the Canadian endMS Research Conference held in Banff, Alberta, from December 10th through the 13th. The work of Drs. Johnson, Yong and Weiss explores prolactin's role as a therapy in acute and chronic central nervous system (CNS) disease settings.

Drs. Weiss and Yong recently published exciting preliminary work on the regenerative effects of prolactin in the Journal of Neuroscience, February 21, 2007 entitled; 'White Matter Plasticity and Enhanced Remyelination in the Maternal CNS'. Interestingly, the study confirmed that pregnant mice have an enhanced ability to remyelinate white matter lesions, explaining the observation that in mammals MS symptoms can subside during pregnancy. This study was novel in that it identified for the first time that prolactin acts to increase the generation of new myelin-forming oligodendrocyte precursor cells, and to increase the number of myelinated axons in the pregnant murine central nervous system (CNS). Most importantly, the finding that prolactin could increase white matter plasticity suggests a striking ability to repair demyelination and identifies prolactin as a potential therapeutic agent.

"We at SCT have been and will continue to support the cutting edge research conducted in the laboratories of Drs. Weiss and Yong," said Dr. Alan Moore, President and CEO of SCT. "We hope to take their work from concept stage to patients with diseases such as MS where there currently is no cure."

The intellectual property encompassing the discovery of prolactin's effect in the CNS by Drs. Weiss and Yong falls within SCT's patent portfolio.

About the Canadian endMS Research Conference: The key goals for this conference are to highlight the wide range of research on MS conducted across Canada, and to introduce the endMS Research & Training Network, a newly developed national initiative funded by the MS Scientific Research Foundation and the MS Society of Canada. The Network is aimed at attracting and retaining the best and brightest minds to train and work in MS research, in order to accelerate the pace of discovery and, ultimately, end this disease.

Key Facts about Multiple Sclerosis (MS):


- Canadians have one of the highest rates of multiple sclerosis in the world.

- MS is the most common neurological disease affecting young adults in Canada.

- Every day, three more people in Canada are diagnosed with MS.

- Women are more than three times as likely to develop MS as men.

- MS can cause loss of balance, impaired speech, extreme fatigue, double vision and paralysis.

- MS was first identified and described by a French neurologist, Dr. Jean-Martin Charcot, in 1868.

- We don't know what causes MS but researchers are closer to finding the answer.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The company's programs aim to repair neurological function lost due to disease or injury. The company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information